A research collaboration between investigators from the Spanish National Research Council (CSIC), the Miguel Hernández University of Elche (UMH), and the École Polytechnique Fédérale de Lausanne (EPFL) has identified a molecule that may could be a new approach to treating Alzheimer’s disease (AD) by restoring the protective functions of microglia, immune cells found in the brain. The findings, published in Cell Death & Disease, said the molecule N-oleoyl-Leucine (OLE), which is derived from the Alzheimer’s disease-associated gene PM20D1, was shown to reduce amyloid pathology, improve cognition, and promote neuroprotection.
“One of the most significant findings is that we have identified a molecule capable of restoring microglia’s protective function,” said senior author José Vicente Sánchez Mut, PhD, principal investigator at the Functional Epi-Genomics of Aging and Alzheimer’s Disease laboratory at the Institute for Neurosciences, a joint CSIC-UMH center. “In Alzheimer’s disease, these cells become progressively impaired. Our results suggest that this process can be reversed, pointing to new therapeutic and research avenues to counteract the disease.”
In recent years, there has been a surge of research into microglia’s role in AD. As the researchers noted, genetic risk variants associated with AD are enriched in regions that regulate microglial function, and microglial gene-expression programs have been shown to be altered during disease progression. As the disease advances, microglia proliferate and accumulate around amyloid plaques, but lose their ability to maintain tissue homeostasis and clear amyloid beta (Aβ). At the same time these immune cells take on inflammatory and neurotoxic characteristics.
PM20D1 has been identified recently as a risk gene in the development of AD. It is a quantitative trait locus associated not only with Alzheimer’s disease but also with diabetes, obesity, and other disorders. People exhibiting lower PM20D1 expression have a higher risk of developing metabolic disorders and Alzheimer’s disease. Other prior research studies also showed that PM20D1 overexpression in mouse models reduced amyloid levels and cognitive deficits, making it a potentially fruitful area for additional study.
PM20D1 encodes a secreted enzyme that regulates the conjugation of fatty acids with amino acids, generating compounds known as N-acyl amino acids (NAAA). OLE is one of these amino acids and was selected for further investigation because PM20D1 activity in living organisms appears to favor its production and because OLE levels are strongly correlated with PM20D1 expression in both humans and mice.
“There is increasing evidence of microglia participation in Alzheimer’s disease (AD), which incentives their modulation to intercept the disease,” the researchers wrote. “Here, we describe a new mechanism by which the recently AD-associated Peptidase M20 Domain Containing 1 (PM20D1) instructs microglia to tackle AD.”
To evaluate OLE’s therapeutic potential, the team first tested it in genetically engineered Caenorhabditis elegans worms that produce beta-amyloid, where they showed that OLE treatment reduced protein aggregation and improved mobility. The researchers then administered OLE to APP/PS1 mouse models of AD for three months. Again, the mice demonstrated better performance in memory tests and showed reductions in amyloid plaque burden.
A cellular analyses found that microglia were the cells most responsive to OLE treatment.
“Single-cell analysis allowed us to determine that microglia were the cells that responded most strongly to the treatment,” said first author Victoria Pozzi, PhD, a postdoctoral researcher working in the Sánchez Mut lab. “From there, we observed that the compound helped these cells move toward beta-amyloid plaques and better contain the damage associated with the disease.”
The study also found that OLE increased Aβ chemotaxis and clearance in cultured microglia. In neuronal cultures exposed to Alzheimer’s-related stressors, OLE enhanced cell survival, indicating that the molecule may have direct neuroprotective effects in addition to its effects on immune cells.
The team believes OLE may function as a disease-modifying therapy by altering microglial behavior and reducing amyloid-associated damage, but because OLE was administered systemically in their experiments, more work is needed to determine whether its primary effects occur in microglia or whether it acts independently on multiple cell types. They also plan to investigate whether other N-acyl amino acids have therapeutic potential and whether OLE can influence tau pathology and neurodegeneration.
GLP-1 drugs could act upon impulsive behavior that leads to violence and criminal acts, research suggests.
The study adds to evidence suggesting that these drugs could have benefits outside their widely used action on diabetes and obesity.
Specifically, it suggests that GLP-1 drugs could act upon impulse control and stress-reward systems in the brain relating to substance and alcohol misuse.
“As GLP-1 medications become increasingly widespread, understanding their broader behavioral effects becomes an important public health and criminological question that requires careful study,” said researcher Daniel Semenza, PhD, from Rutgers University.
Recent research has suggested that GLP-1 receptor agonists (RAs) such as exenatide, liraglutide, semaglutide, and dulaglutide have benefits beyond glycemic control and weight loss.
These include reducing the risk of multiple psychiatric and neurocognitive conditions and improving impulse control.
Semenza and Christopher Thomas, also from Rutgers, examined the relationship between the use of GLP-1 drugs and violent behavior using recent survey data from 821 U.S. adults in a 2025 nationally representative survey who had used these medications at some point in their lives. Of these, 597 were current users and 224 were former users.
Given established connections between aggression, alcohol use, and impulsivity, they also investigated whether current GLP-1 use was associated with a lower risk of violence by moderating the associations of impulsivity and alcohol use with violent crime.
The team found that impulsivity and alcohol use were strongly associated with committing violent crime. Each standard deviation increase in impulsivity was associated with a 1.9-fold increase in violence, and each unit increase in an alcohol use index was associated with a 1.8-fold increase.
However, current GLP-1 receptor agonist use was associated with significantly weaker associations between either impulsivity or alcohol use and violent crime compared with former GLP-1 drug use, attenuating these by approximately 62% and 52%, respectively.
This meant that even when users of GLP-1 receptor agonists drank alcohol or acted impulsively, it would be less likely to lead to violent crime.
The relationship was particularly strong relating to impulsivity and less so with alcohol use.
“Understanding the neurobiological mechanisms by which GLP-1 receptor signaling may moderate impulsivity-related risk pathways represents an important research opportunity,” the researchers concluded.
“Given the rapidly expanding use of GLP-1 receptor agonists throughout the United States and the rest of the world, this pattern of reduced violence risk warrants ongoing attention from both researchers and policymakers.”
A vibrating capsule that assesses how nerve signals from the stomach are registered by the brain could help identify patients with anorexia at risk of relapse, a clinical trial suggests.
The findings, in JAMA Psychiatry, offers an insight into how the eating disorder affects the nervous system as well as a way to personalize and assess the success of treatment.
The results suggest that disruptions in gastrointestinal (GI) interoception—involving the detection, transmission, and processing of signals in the digestive tract—can increase the risk of anorexia returning, even if weight has normalized.
Gastric signals could therefore act as scalable biomarkers to identify who is at increased risk of relapse and track whether treatment is improving gut-brain signaling.
“People with anorexia nervosa do not simply ignore signals from the body,” explained researcher Sahib Khalsa, PhD, at the University of California, Los Angeles.
“Rather, their nervous system may process gut sensations differently, making those signals harder to detect, trust and learn from. Over time, that may contribute to the persistence of symptoms even after weight is restored.”
Khalsa and co-workers asked 62 girls and women with anorexia nervosa whose weight had been restored to healthy levels to swallow the vibrating capsule in their crossover trial.
The capsule could be remotely controlled by the researchers to produce mechanosensory stimulation of different intensities in the stomach.
Participants were asked to press a button upon sensing a vibration, with 54 patients followed up at six months after discharge from hospital and their results compared with 57 healthy control individuals.
Computational modeling was used to estimate how strongly participants anticipated feeling sensations in their stomachs, how heavily their brains depended on body signals, and how quickly they adjusted their expectations as to the presence or absence of signals.
The researchers found that participants with anorexia had abnormal GI interoception across behavioral and computational domains compared with healthy participants, despite having intact neural and physiological responses.
Participants with anorexia were less able to detect subtle stomach sensations and were more likely than others to believe there were no sensations when the pill was vibrating. They were also less likely to update those expectations when gastric signals occurred.
Patients who were more likely to ignore the stomach signals were also at increased likelihood of relapsing to the eating disorder.
“One of the most striking findings was that these differences persisted even after weight restoration,” said Khalsa.
“Recovery from anorexia nervosa isn’t just about restoring body weight. The underlying brain–body communication problems may remain and could contribute to relapse.”
The researchers conclude that their results support the use of ingestible mechanosensory probes and computer modeling as scalable tools to monitor treatment response and guide relapse prevention in eating disorders.
Bacterial expression systems are becoming more versatile, say Swedish contractor NorthX Biologics and Austrian technology firm enGenes Biotech, who have teamed up to create an integrated, E.coli-based protein production platform.
E.coli-based protein expression systems are not a new idea. They have been around since the 1970s and used to make everything from recombinant human insulin to treatments for growth hormone deficiency.
They are generally cheaper than expression systems that use mammalian cells, primarily due to lower reagent costs. They also tend to be faster to set up, easier to scale, and have a reduced risk of viral contamination.
Typically, E.coli-based systems are selected for the manufacture of simple proteins that do not require human-like post-translational modifications such as glycosylation. However, recent advances in strain engineering are starting to expand their scope.
As a result, more biopharmaceutical firms are considering them for commercial-scale protein production, says Ola Tuvesson, CTO at NorthX, who cites this demand as a driver for the enGenes partnership.
“The biggest growth vectors are biosimilar manufacturing, peptide therapeutics, and antibody fragments, including ADC components. Advances in glycosylation engineering are also expanding what the platform can address at the higher end of biologics complexity.
“Several trends are reinforcing this direction: sustained pricing pressure pushing biopharma away from higher-cost production systems for this segment of the pipeline, growing investment in CRISPR-based strain engineering that extends microbial platforms into more complex program types, and a manufacturing infrastructure that needs to keep pace with industry demand,” Tuvesson tells GEN.
Integrated pathway
NorthX Biologics and enGenes’ strategy is to offer an integrated service that covers everything from strain design through manufacture.
Tuvesson says, “The E. coli development to GMP manufacturing pathway typically covers expression system development, process development, scale-up, and transfer into GMP production. While the technical steps are well established, the challenge in many programs is that these stages are often handled by different providers, leading to delays, rework, and increased scale-up risk.
“The pathway we are establishing addresses this fragmentation by integrating expression development and GMP manufacturing into a single, aligned workflow. This reduces handovers, improves data continuity, and helps ensure that the expression system is optimized from the start for manufacturing at scale,” he adds.
The new pathway will combine high-throughput screening platforms, multi‑fermenter systems, and multivariate experimental design with advanced analytical support and scale-up engineering.
According to NorthX Biologics and enGenes Biotech, the idea is to enable rapid iteration and the generation of decision-grade data early in development, supporting more robust and scalable processes.
There is an option to extend the partnership, according to Tuvesson, who says, “The collaboration may also open up opportunities to implement more continuous manufacturing approaches over time.”
The firms plan to monetize the platform by providing it to biopharma customers as a manufacturing service, rather than out-licensing, as Tuvesson explains.
“Expression systems and processes developed for a specific protein can be transferred under standard commercial terms. However, the pathway itself is not a standalone licensable product.
“The focus is instead on integrating expression development and manufacturing into a single workflow, reducing handovers and enabling faster development timelines,” he says.
Jonathan D. Grinstein, PhD, North American Editor of Inside Precision Medicine, hosts a new series called Behind the Breakthroughs that features the people shaping the future of medicine. With each episode, Jonathan gives listeners access to his guests’ motivational tales and visions for this emerging, game-changing field.
Philippe Pouletty, MD, is one of Europe’s most accomplished life sciences entrepreneurs, with a track record of creating category-leading companies in both biotechnology and medical technology. Over more than three decades, he has repeatedly identified breakthrough scientific innovations, assembled world-class teams, and scaled businesses from inception to global prominence.
His most celebrated success is Abivax, the biotechnology company he founded and led as chairman for a decade. Under his leadership, Abivax evolved into a global biotechnology powerhouse, achieving an approximately $10 billion market capitalization after positive Phase III results in 2025. In 2025, the company delivered the strongest stock market performance of any European company across all sectors.
Philippe Pouletty, MD, Co-founder and CEO of Truffle Capital and Co-founder of Abivax and Carvolix. [Truffle Capital]
Today, Philippe Pouletty is applying the same entrepreneurial playbook to Carvolix, a next-generation cardiovascular MedTech company focused on heart valve disease and stroke. Carvolix is built on the strategic combination of breakthrough implant technologies, AI-powered software, and autonomous mini-robotics. The vision follows the successful Abivax model: bring together differentiated technologies, speed up industrialization, build clinical leadership, and create a company that can transform patient outcomes while attracting significant strategic and public-market value.
A physician, scientist, inventor, and venture capitalist, Philippe has founded or co-founded numerous successful life sciences companies and holds dozens of patents, including one of Stanford University’s highest-revenue-generating life sciences inventions. With Abivax and now Carvolix, he has demonstrated a rare ability to build transformative healthcare companies that combine scientific innovation, commercial scale, and lasting impact for patients worldwide.
This interview has been edited for length and clarity.
IPM: Having spent time in both Silicon Valley and Europe, what cultural or structural differences have you discovered that have given Europe an advantage in deep tech and life sciences or that may be holding it back when compared to companies in the United States?
Pouletty: In California, financial resources are virtually limitless as long as you have a company with a great mission that addresses large medical needs and markets. Unfortunately, Europe is behind. France is an excellent place to begin, with companies to hire, good engineers, management, and so on. However, raising more than €50 or €60 million is often difficult when compared to the United States. So, things have improved over the last two decades, and there are some good grants and tax breaks available to help businesses raise capital.
However, the stock market in France and Europe is not as competitive as the Nasdaq. So, while I love the United States, many French and European companies must list on Nasdaq in order to grow, remain independent, and eventually reach the commercial stage. Then it becomes an American company, often a large pharmaceutical company or one with significant innovation. Wonderful small company. Let us buy it. So that’s great for the United States and big pharmaceutical companies. However, Europe’s prospects for the next 20 years do not look promising. The challenge for Europe is that competition will primarily come from the United States, China, and, most likely, India.
Europe faces a difficult task in catching up. But, because I’m still a crazy entrepreneur who is interested in European policies, it’s time for France and Europe to do the right thing and establish independent companies. I believe what is of interest is to do things that have an impact on patients. And if you have a positive impact on patients, you will increase shareholder value; however, you should not always focus on doing an IPO or selling the company as soon as possible. What matters is developing completely novel, radical innovation that will change or prolong the lives of patients while also benefiting the environment.
IPM: As one of Europe’s standout biotech success stories, what set Abivax apart from the many biotech companies that never scale beyond promising science in Europe before venturing out west?
Pouletty: What we like to do at Abivax and Carvolix is build businesses by merging two or three of our biotech companies when much of the R&D is completed in order to reach critical mass and have several product candidates available. So if one fails, the company is not doomed. To be able to attract extremely experienced management. There are too many very small businesses in Europe. For example, the president, Emmanuel Macron, likes to refer to France as the “startup nation.” The goal should not be to become the startup nation. The goal should be to develop world leaders similar to those in the United States, regardless of sector.
Abivax emerged in 2013. Three of our biotech companies were able to complete a Euronext IPO, which remains the largest biotech IPO on Euronext. We had raised €58 million at the time. Surprisingly, the most advanced product candidate, a drug candidate, failed following the IPO in phase two. So it was unpleasant but not disastrous because the second product candidate, which was only in phase one at the time, is now assembled, has a $7 to $10 billion valuation, and has had excellent results in phase three in treating ulcerative colitis patients.
So, it appears to be a straightforward business plan. It’s not correct. You must stay focused on your mission. Disappointment can occur during pre-clinical R&D and clinical development. Of course, this happens to the majority of biotech companies. And this is why, for example, when sailing across the Atlantic or Pacific, you must keep in mind that reaching the other side requires a strong team; sometimes we change the team and the CEO.
But we are very proud to say that the above acts would not exist without Truffle Capital, and I was chairman of the board for ten years and was very pleased. it looks like the drug should be approved. In the last few days the stock dropped because the long-term maintenance clinical results showed great efficacy and there were very few cancers, which is typical in this kind of patient population with a dysfunctional immune system.
So to me, it’s a little hiccup, but I’m very confident it will change and improve the lives of the patients with ulcerative colitis. Now, maybe the little drop in valuation will boost the M&A appetite of some big pharma companies. And I can send that because, well, not any more shareholders are involved in the epilogue. It’s my personal opinion, of course, about the future. I could be wrong.
IPM: How do emerging European companies like Carvolix or Abivax compete with American or Chinese companies? Do you try to establish a market in Europe first, then expand internationally, or do you try to do everything at once? What’s your strategy there?
Pouletty: When Carvolix first launched in the United States, the largest market was heart valve software. So, while launching in the United States with a very concentrated focus team, step by step with specialized centers and then with the market, research based on this successful launch will expand. We may later hire a partner for the United States, or agents or a single partner.
We want our products to be agnostic, regardless of whether the valve is Abivax, Medtronic, or Abbott, so that hospital clinicians can choose which valve system to use for their patients with our software and robot. We will continue to conduct direct sales in Europe, as we have in the past. If you have a highly innovative product, you will need a small, highly technical sales force that can visit clinics, hospitals, and clinicians to be successful in Asia.
IPM: How do you get clinicians and hospitals to buy into something like this, which isn’t really an upgrade of their system, but rather the introduction of a whole new line?
Pouletty: At first, we assumed that top-tier cardiologists who treat hundreds or thousands of patients would not require our services. And it will primarily benefit younger, less-trained cardiologists. However, we conducted studies in France with data from the world’s leading cardiologist for aortic valve replacement, as well as in Australia with highly trained cardiologists. They said, “That’s great because I’m less stressed during the implantation.” I may not need a second cardiologist in the room, as is frequently required, and I may see more patients during the day.
It’s somewhat similar to cars. You could argue that autonomous cars will not meet the needs of taxi drivers. But yes, taxi drivers will say, “Great.” I can drive more miles, transport more passengers, and feel more relaxed at the end of the day. I have no doubt that it will become the norm in medium and small hospitals over the next few years. Place special patients in the care of an expert cardiologist. Now for given special patients in the hands of an expert cardiologist, we don’t pretend it will do better. But many more patients who have not the chance, whether it’s hardware replacement or brain stroke treatment to healthcare… will if we are successful.
It is critical to ensure that introducing AI and robotics does not prolong the procedure. It takes roughly the same amount of time or appears to be shorter. However, it is always under clinical supervision. We can take over and stop the procedure, just like on a plane, and carry it out manually. However, after some initial training with a few patients, the clinician will most likely allow the procedure to be completed autonomously while closely monitoring the screen to ensure that everything is running smoothly.
IPM: How do European healthcare systems differ in their ability to adopt new biotech and medtech innovations?
Pouletty: No system is perfect. I do a very simple comparison in France and Europe. even patients who do not work will be treated in the hospital at no cost. In the U.S., you’d better have a plan. You’re working in the company to be covered. There is no perfect system. Certainly, pricing of drugs and medical devices in the U.S. is higher, which means that there is an incentive for investors and companies to do high-cost R&D to recoup their investment through high pricing. In France and Europe, there is a tendency to have to push for low pricing and low reimbursement, which is why for oncology drugs more are available and reimbursed in the U.S. today than for non-college products.
But there is not enough emphasis on the long-term impact of innovation. And pioneers often looked at the shorter impact and said, oh, that’s two weeks, let’s say. I’ll give you one example. In oncology, pancreatic cancer is tough because the diagnosis is very often very late when you have big tumors.
It’s very clear that if it were up to me, we would do imaging every two years. We would catch very small, tiny tumors very early on because an anatomical change in our cells within two years could indicate that you need to go and see if you should remove this little tiny one. But that’s not common in practice because it would be expensive to do an MRI every two years on everyone after 50 years old.
So beyond drugs and medical devices and the practice of medicine, how do you do? Preventative medicine needs to be greatly improved, and governments are not very good at looking at these approaches to improve healthcare. So, I went into politics. I would turn on that. I decided 25 years ago I would not run for any elected office and focus more on starting companies.
This is today’s edition of The Download, our weekday newsletter that provides a daily dose of what’s going on in the world of technology.
Hacking the atmosphere: geoengineering gets a reality check
Solar geoengineering, the controversial idea that we could deliberately intervene in the climate system to counteract global warming, is moving beyond computer simulations and into the practical engineering challenges required to make it real.
Researchers are now working on aircraft, materials, and other systems for solar geoengineering. But as they delve into these details, they’re finding that even early deployment would require significant new infrastructure, time, and investment.
MIT Technology Review Narrated: inside interoception, the hidden sense of how you feel inside
Scientists have a word for how we sense ourselves from the inside: interoception. Today, thanks to a 2021 Nobel Prize and new tools that can map internal signaling across the body, research into interoception is taking off.
This is our latest story to be turned into an MIT Technology Review Narrated podcast, which we publish each week on Spotify and Apple Podcasts. Just navigate to MIT Technology Review Narrated on either platform, and follow us to get all our new content as it’s released.
The must-reads
I’ve combed the internet to find you today’s most fun/important/scary/fascinating stories about technology.
1 SpaceX is now valued higher than Amazon Its market value hit $2.659 trillion yesterday. (Axios) + A post-IPO stock surge also briefly pushed it above Microsoft’s. (Quartz) + It’s now the world’s fifth most valuable company. (Guardian) + SpaceX is acquiring AI coding startup Cursor for $60 billion. (CNBC)
2 G7 leaders want access to top US AI models They’re pushing to escape restrictions on the likes of Fable 5. (Reuters $) + The Mythos shutdown has sparked a global scramble for sovereign AI. (Fortune) + The world is looking to ditch US AI models. (MIT Technology Review)
3 Trump’s AI export strategy has run into Trump’s export controls His administration risks undermining its own AI plans. (Axios) + It now effectively has a licensing regime for frontier AI. (Fortune) + Here’s how a top Chinese AI model overcame US sanctions. (MIT Technology Review)
4 Huawei’s big comeback has exposed the limits of US chip controls It’s overcome restrictions on advanced chipmaking gear. (Financial Times $) + The AI boom has ignited Asia’s chip companies. (NYT $)
5 AI fears are pushing Silicon Valley toward gene-editing startups They want smarter babies to counter superintelligent AI. (Mother Jones) + The pursuit of perfect babies is an ethical mess.(MIT Technology Review)
6 A brain implant has enabled a speechless ALS patient to work full-time The system translates his brain activity into speech. (The Register) + He’s become the first “power user” of a BCI. (MIT Technology Review)
7 A leak has revealed details of Peter Thiel’s secret society Its program ranges from cult-building to prepping for World War III. (Wired $)
8 ChatGPT’s market share has slipped below 50% for the first time Thanks to the rise of Gemini and Claude. (TechCrunch)
9 A quantum state that lasts forever may finally be within our grasp Experiments suggest that quantum “eternity” is possible. (New Scientist $)
10 Commodore has made a digital detox phone that isn’t dumb The Callback combines gadget nostalgia with modern needs. (The Verge)
Quote of the day
“The Entity List is like whack-a-mole and you’ve got to keep whacking the moles.”
—Philip Luck, who studies global supply chains at the Center for Strategic and International Studies, tells Reuters that a lack of new blacklistings is likely leading American innovations to adversaries who could use them against the US.
One More Thing
COURTESY OF DEEPMIND
This is the reason Demis Hassabis started DeepMind
Watching DeepMind’s AI master the ancient board game Go, Demis Hassabis realized that his company was ready to take on one of the most important and complicated puzzles in biology: predicting the structure of proteins.
The result was AlphaFold2, an AI that could predict the shape of proteins down to the nearest atom. “It’s the most complex thing we’ve ever done,” Hassabis told MIT Technology Review.
Taking on scientific problems is the culmination of what Hassabis set out to achieve, and it’s what he wants to be known for. “This is the reason I started DeepMind,” he says. “In fact, it’s why I’ve worked my whole career in AI.”
A place for comfort, fun, and distraction to brighten up your day. (Got any ideas? Drop me a line.)
+ This mesmerising footage of wind rolling through grass looks like CGI. + The glorious early days of internet discovery have been revived by the return of StumbleUpon. + A German subway entrance has been delightfully designed as an old tram car crashing into the pavement. + The Last Museum lets you search across 5.8 million museum artworks spanning from 3000 BC to the present day.
The Danaher Bioprocessing Summit, “The Next Era of Bioprocessing: From Promise to Patient Impact,” took place in London earlier this month. The event brought together officials from Danaher companies (Cytiva, Pall, Beckman Coulter Life Sciences, IDBS, and Leica Microsystems), along with biopharma manufacturers and researchers to discuss how the industry can accelerate the transition from scientific breakthroughs to commercial therapies.
Key themes included:
AI-driven bioprocess development and manufacturing
Intensified and continuous bioprocessing
Digitalization and connected data ecosystems
Improving productivity and reducing cost of goods
Cell and gene therapy manufacturing challenges
Scaling production of high-demand biologics, including GLP-1 therapies
Advanced analytics and process control
Sustainability in biomanufacturing
The conference emphasized that future competitive advantage in biomanufacturing will come less from building additional capacity and more from increasing productivity, speed, and process intelligence across the development-to-manufacturing workflow.
Based on the formal presentations, roundtable discussion groups, and conversations among speakers, panelists, and attendees, six key takeaway ideas emerged.
The old manufacturing playbook no longer fits
Biomanufacturing was built for large batches of standardized therapies. The next generation of medicines—cell and gene therapies, targeted and complex biologics, N-of-1 treatments—doesn’t fit that mold. As molecular diversity increases, the field is shifting toward smaller, parallel and distributed systems that can flex to meet the complexity of individualized medicine. This means faster decision-making, new investment models, and process designs that are data-driven and purpose-built from the start rather than adapted from previous playbooks.
Manufacturing can no longer be treated as a downstream problem. It has to be part of the scientific conversation from day one.
Automation and AI are making personalized scale possible
For years, the promise of personalized medicine ran into a hard wall: you can’t manufacture one patient’s therapy the same way you manufacture a million doses of a traditional drug. Integrating automation, AI and high-throughput experimentation is changing that equation.
These tools are enabling a shift from large-batch production to small-batch and even patient-specific manufacturing while improving efficiency, regulatory consistency, and access to advanced therapies. AI and digital tools are also compressing process development timelines, making it possible to design more tailored, adaptive manufacturing approaches without sacrificing rigor.
Prediction is becoming a competitive advantage
The organizations gaining ground are not merely reacting to problems faster but actually anticipating them. Digital twins powered by integrated data are helping teams model outcomes before committing resources, accelerating timelines and reducing risk. And real-time, molecular and submolecular-level data—shared across interoperable systems—are enabling more precise, proactive decision-making at every stage of development and manufacturing. Investing in this area with critical infrastructure is essential.
Breakthroughs require collaboration across the whole ecosystem
It turned out that the most consistent theme across both days of the Summit was this: no single organization can accomplish what’s needed alone. Partnerships across academia, industry, and regulators are accelerating how all kinds of therapies, especially gene therapies, move from discovery to approved treatment. Earlier alignment between developers, manufacturers, and regulators is reducing friction and compressing timelines.
A central theme surfaced throughout the conference: the science is not the problem. The bioindustry already possesses powerful technologies and therapeutic capabilities. Future success depends on rapidly implementing them through manufacturing, regulatory alignment, supplier collaboration, and partnerships. Organizations that execute most effectively will shape the next decade of medicine. [Danaher]
What makes these partnerships work is not goodwill alone but transparency, shared incentives, and data-driven collaboration that keeps everyone oriented around the same outcomes. The organizations making the most progress are those treating collaboration as a core capability.
Regulatory models are evolving with the science, and sustainability is now a procurement requirement, not a values statement
Most of the frameworks that currently govern drug development were built for an earlier era of medicine. As therapies grow more complex and more personalized, those frameworks must change. Early engagement and risk-based approaches are helping bring complex therapies to patients faster without compromising scientific rigor. For rare diseases, which collectively affect an estimated 300 million people worldwide, tailored regulatory pathways are becoming essential.
Summit speakers agreed that regulators are not the obstacle they’re sometimes assumed to be. They want to move faster too, and building the right collaborative infrastructure makes that possible.
Environmental and social criteria are moving from corporate commitments into day-to-day supplier decisions. Organizations are integrating sustainability standards into procurement frameworks, requiring verified supplier commitments and shared performance targets as part of doing business.
Far from being separate from operational strategy, this is part of building supply chains resilient enough to support long-term innovation at scale. Progress toward net-zero goals, Summit participants agreed, accelerates when sustainability is wired into commercial relationships rather than managed alongside them.
Across two days and numerous conversations, one key point kept surfacing: the science is not the problem. The biopharma industry has the tools, the knowledge, and the therapeutic advances to transform how medicine is made and delivered. What it lacks is the collective will to operationalize them at speed. The next phase of progress will be won in manufacturing facilities, regulatory negotiations, supplier contracts, and partnerships that connect all of them.
The final conclusion: organizations that close the gap first will define what the next decade of medicine looks like.
To watch recorded keynote presentations, panel discussions, and fireside chats from the Danaher Summit on Bioprocessing, click here.
Rise and shine, everyone, another busy day is on the way. And it is getting off to a pleasant start here on the Pharmalot campus, where clear blue skies and comfy breezes are greeting us. Moreover, the official mascots succeed in spotting various varmints — foxes and possums, to be specific, but thankfully, no vultures. As for us, we are heating our spiffy new replacement kettle for another cuppa stimulation. Our choice today is old-fashioned green teas. And here is a helpful tip — a teaspoon of honey enhances the flavors splendidly. Of course, you are invited to join us. For the full experience, we are now hawking replicas — take a look. Meanwhile, here are a few items of interest. As always, do keep in touch. We appreciate feedback, criticism, and tips. …
Weight loss drugs will be available to adults 65 and older in Medicare for the first time next month, thanks to a government program that is supposed to be temporary — but it may be difficult to end,STAT explains. By law, Medicare is prohibited from paying for obesity drugs, but the Trump administration is circumventing the law by making the drugs available in a demonstration program. Initially, Medicare hoped to push private Medicare insurers to voluntarily cover the drugs in a three-year program called Balance, which would have started following a short transitional period. But insurers balked, so the government is instead extending the transitional coverage program, called Bridge, until the end of next year.
Novo Nordisk chief executive officer Mike Doustdar said the company plans to seek Chinese regulatory approval for its Wegovy weight loss pill “very soon” as it moves to catch up with Eli Lilly in the world’s second-largest pharmaceutical market, Reuters tells us. The patent for semaglutide, the active ingredient in Novo’s blockbusters Wegovy and Ozempic, expired in China in March, though the company has regulatory data protection until early next year. Doustdar said he expected competition from generic drugmakers from the second quarter of next year. Novo won early approval in the U.S. and the U.K. for its Wegovy pill and launched it in the U.S. this year. Lilly followed quickly, securing U.S. approval in April for its oral drug orforglipron.
![A central theme surfaced throughout the conference: the science is not the problem. The bioindustry already possesses powerful technologies and therapeutic capabilities. Future success depends on rapidly implementing them through manufacturing, regulatory alignment, supplier collaboration, and partnerships. Organizations that execute most effectively will shape the next decade of medicine. [Danaher]](https://www.genengnews.com/wp-content/uploads/2026/06/capacity_scale_panel_dhr_summit2026.jpg)